Skip to main content
Premium Trial:

Request an Annual Quote

Down the Pike

Chris at R&D Directions Insider blog spoke with both Merck's Alan Sachs and Amgen's Sean Harper down at the BIO meeting in Atlanta. Sachs is a VP of RNA Therapeutics and tells Chris that Merck isn't focusing on the delivery of RNA-based drugs but instead is looking whether RNA-based drugs make be safely taken for a chronic condition. Harper says that FDA has accepted Amgen's new drug application for denosumab to treat postmenopausal osteoporosis and bone loss from hormone ablation therapy. He adds that Amgen is also working on cancer therapies and treatments for asthma.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.